The bases remain similar to those in DNA, allowing PNAs to target transcripts. As antisense molecules, PNAs bind to complementary messenger RNA (mRNA), blocking its function and inhibiting the ...

In this phase I trial, Lai and colleagues evaluated the safety and toxicity of EGFR antisense DNA therapy in 20 patients with advanced squamous-cell carcinoma of the head and neck. All patients ...

The scientists at the University of California, San Francisco, and Johns Hopkins University in Baltimore injected an ...

U of A professor of medical genetics Toshifumi Yokota and the Yokota Lab are making advancements in gene therapy.

Scientists use short oligonucleotides as primers for polymerase chain reaction and next-generation sequencing, in DNA microarrays and fluorescence in situ hybridization, and in antisense therapies. (1 ...

An antisense drug in development at GSK has shown ... reduced levels of hepatitis B surface antigen (HBsAg) and HBV DNA after 24 weeks' treatment to below the lower limit of detection in people ...

Researchers from Osaka University have developed a novel approach to target nicotinamide N-methyltransferase (NNMT), an enzyme implicated in cancer progression, using antisense oligonucleotides (ASOs) ...

The treatment is antisense oligonucleotide therapy, commonly called ASO. This type of genetic therapy uses short, synthetic DNA sequences to target specific mRNA. N-Lorem, a California-based ...

As surprisingly high proportions of eukaryotic genomes are transcribed, with numerous noncoding and antisense RNAs being ... from evolutionarily unrelated DNA is noise, so analysis of cells ...